Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCMA-CD19 cCAR-T
- Development stage
- Phase 1
- Lead developer
- iCell Gene Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
BCMA-CD19 cCAR-T is a compound chimeric antigen receptor T cell therapy developed by iCell Gene Therapeutics. It targets both B-cell maturation antigen (BCMA) and CD19, aiming to reset the humoral and B cell immune system. This therapy is primarily being explored for its potential in treating autoimmune diseases like systemic lupus erythematosus (SLE) and multiple sclerosis, as well as hematological conditions such as multiple myeloma and lymphoma. The mechanism involves immunologic cytotoxicity through T lymphocyte replacement.
- Other names
- BCMA-CD19 cCARBCMA-CD-19 cCARBCMA-CD 19 cCARCompound BCMA-CD19 CAR T cells
02
Targets
BCMA (B-cell maturation antigen)CD19 (B lymphocyte antigen CD19)
Beyond the preview
Go deeper on BCMA-CD19 cCAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCMA-CD19 cCAR-T.